



# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Anticholinergics, Long Acting Inhaled PDL Edit
<b>First Implementation Date:</b>	October 26, 2018
<b>Revised Date:</b>	August 31, 2023
<b>Prepared For:</b>	MO HealthNet
<b>Prepared By:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** Asthma is a chronic inflammatory disorder of the airways characterized by reversible episodes of chest tightness, shortness of breath, cough, or wheezing. Severity is determined by multiple factors including frequency of symptoms, FEV<sub>1</sub> and FEV<sub>1</sub>/FVC measurements, and frequency of exacerbations. Approximately 25 million individuals are impacted by asthma, including 6 million children under the age of 18. The condition, although often manageable with lifestyle changes, pharmacologic therapies, and trigger avoidance, continues to be a significant health and economic burden.

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities. It continues to be a leading cause of morbidity and mortality worldwide. Pharmacological therapy is used to reduce COPD symptoms and reduce the frequency and severity of exacerbations. Treatment regimens are individualized based on symptom severity, exacerbation risk, comorbidities, and patient ability to effectively manage and utilize the various drug delivery devices.

Many of the currently available pharmacologic therapies utilized for the treatment and management of asthma and COPD overlap in their FDA-approved indications. Choice of therapy is guided by disease severity, prior therapies utilized, product cost, patient ability to properly use the various delivery devices, potential side effects, concomitant disease states, and ability to maintain adherence to the therapy regimen.

Total program savings for the PDL classes will be regularly reviewed.

### Program-Specific Information:

Preferred Agents	Non-Preferred Agents
<ul style="list-style-type: none"> <li>Spiriva HandiHaler®</li> <li>Spiriva® Respimat®</li> </ul>	<ul style="list-style-type: none"> <li>Incruse Ellipta®</li> <li>Lonhala® Magnair®</li> <li><b>Tiotropium inhaler</b></li> <li>Tudorza Pressair®</li> <li>Yupelri®</li> </ul>

Type of Criteria:  Increased risk of ADE  
 Appropriate Indications

Preferred Drug List  
 Clinical Edit

Data Sources:  Only Administrative Databases

Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Anticholinergics, Long Acting Inhaled
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- For non-preferred agents:
  - Documented compliance on current therapy regimen **OR**
  - Failure to achieve desired therapeutic outcomes with trial on 1 or more preferred agents
    - Documented trial period of preferred agents **OR**
    - Documented ADE/ADR to preferred agents **AND**
  - For Lonhala Magnair: Documented therapeutic trial of Yupelri

## Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

## Required Documentation

Laboratory Results:   
MedWatch Form:

Progress Notes:   
Other:

## Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)  
Rule Type: PDL

## Default Approval Period

1 year

## References

- Evidence-Based Medicine and Fiscal Analysis: "Therapeutic Class Review: RESPIRATORY: Anticholinergics, Long Acting Inhaled", Gainwell Technologies; Last updated February 6, 2023.
- Evidence-Based Medicine Analysis: "Anticholinergics, Long Acting", UMKC-DIC; Last updated October 2022.
- Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD 2021 report). <https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf>.
- USPDI, Micromedex; 2023.
- Update on Selected Topics in Asthma Management: A Report from the NAEPPCC Expert Panel Working Group (2020 Focused Update to the Asthma Management Guidelines).  
<file:///C:/Users/mfast/Downloads/AsthmaManagementGuidelinesReport-2-4-21.pdf>.

*SmartPA PDL Proposal Form*

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.  
Other company trademarks are also acknowledged.

- Facts and Comparisons eAnswers (online); 2023 Clinical Drug Information, LLC.